Search | Clinical Trials Finder

Conditions: Stroke, Transient Ischemic Attack
Interventions: tailored intervention, attention placebo; Behavioral
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions: Cipherome Lighthouse Pilot; Diagnostic Test
Lead sponsor: Cipherome, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Edinburg, Texas

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Dulaglutide, Semaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 70,000 participants
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Ischemic Stroke
Interventions: Penumbra System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 205
States / cities: Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more

Conditions: Stroke, Myocardial Infarctions
Interventions: Clopidogrel, Aspirin 81 mg, Aspirin >300 mg; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Disease
Interventions: Rimonabant, Placebo (for Rimonabant); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 18,695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
Interventions: Vitamin D3; Biological
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 545
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease
Interventions: Hemotag; Device
Lead sponsor: Aventusoft, LLC.; Industry
Eligibility: 40 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin; Drug
Lead sponsor: Baim Institute for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 25,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 178
States / cities: Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more

Conditions: Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Interventions: ISCDX blood test; Diagnostic Test
Lead sponsor: Ischemia Care LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions: Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 21,379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 250
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more

Conditions: Vascular Death, Myocardial Infarction, Stroke, Cardiac Surgery
Interventions: Not listed
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15,989 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 13,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 242
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more

Conditions: Intracerebral Infarcts, Ischemic Stroke, Hemorrhagic Strokes, TIA's
Interventions: DESERVE education; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: New York, New York

Conditions: Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke of Basilar Artery, Cardioembolic Stroke
Interventions: Biomarker blood draw; Other
Lead sponsor: Ischemia Care LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 22
States / cities: Sacramento, California • San Francisco, California • Detroit, Michigan + 17 more

Conditions: Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control; Other
Lead sponsor: Andrew Slivka; Other
Eligibility: 40 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: TQJ230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 287
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more

Conditions: Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest, PTSD
Interventions: Written Exposure Therapy; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Imaging Guided Patient Selection for Interventional Revascularization Therapy

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

The Dual Antiplatelet Therapy Study (DAPT Study)

Biomarkers of Acute Stroke in Clinic

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Discharge Educational Strategies for Reduction of Vascular Events

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)